Published in J Bacteriol on January 01, 1967
Molecular aspects of endotoxic reactions. Bacteriol Rev (1969) 3.85
A purified group A streptococcal pyrogenic exotoxin. Physiochemical and biological properties including the enhancement of susceptibility to endotoxin lethal shock. J Exp Med (1970) 3.76
Detection of delayed hypersensitivity in mice injected with ribonucleic acid-protein fractions of Salmonella typhimurium. Infect Immun (1972) 1.64
The role of endotoxin in protection of adult rats from oxygen-induced lung toxicity. J Clin Invest (1978) 1.08
Stimulation of heme oxygenase in macrophages and liver by endotoxin. J Clin Invest (1974) 0.95
Inhibition of macrophage migration by nucleotide-containing streptococcal preparations. Infect Immun (1973) 0.85
Inflammatory mediators in culture filtrates of Escherichia coli. Am J Pathol (1975) 0.84
Comparison of the capillary tube and explant methods for the in vitro assay of tuberculin. Infect Immun (1973) 0.78
Studies on the O antigen of Salmonella typhosa. I. Purification of the antigen. J Immunol (1955) 6.88
Bacterial pyrogens. Pharmacol Rev (1957) 4.35
Preparation and host-reactive properties of endotoxin with low content of nitrogen and lipid. J Exp Med (1961) 3.84
The lethal effect of endotoxins on the chick embryo. J Exp Med (1956) 3.62
Symposium on bacterial endotoxins. I. Relationship of chemical composition to biological activity. Bacteriol Rev (1961) 3.48
A method for titrating endotoxic activity in the skin of rabbits. J Exp Med (1960) 2.98
OBSERVATIONS ON MODE OF ACTION OF ENDOTOXIN IN CHICK EMBRYOS. Proc Soc Exp Biol Med (1964) 2.46
Hypoferremia in mice and its application to the bioassay of endotoxin. J Bacteriol (1965) 2.25
QUANTITATIVE ASPECTS OF THE PYROGENIC RESPONSE OF RABBITS TO ENDOTOXIN. J Lab Clin Med (1965) 2.22
BACTERIAL ENDOTOXEMIA. Annu Rev Med (1965) 1.51
Tissue culture methods for studying delayed allergy: a review. Tex Rep Biol Med (1963) 1.05
HYPERREACTIVITY TO ENDOTOXIN AFTER INFECTION WITH BCG. J Immunol (1964) 0.98
EFFECT OF ENDOTOXIN ON MACROPHAGES OF THE ADULT CHICKEN. Proc Soc Exp Biol Med (1965) 0.95
The effect of endotoxin on tissue cultures of spleen of normal and tuberculin-sensitive animals. Am Rev Respir Dis (1961) 0.92
Effect of dosage on endotoxin-induced changes in the reticuloendothelial system of rabbits. J Reticuloendothel Soc (1965) 0.83
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (1989) 4.13
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A (2000) 3.61
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Functional anatomy of the lymphocyte in immunological reactions in vitro. J Exp Med (1966) 2.91
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 2.53
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol (1992) 2.43
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A (1999) 2.00
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol (1971) 1.84
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res (1984) 1.83
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene (1999) 1.81
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res (2001) 1.77
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer (1999) 1.73
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med (1988) 1.67
BCG and cancer. N Engl J Med (1974) 1.66
Inhibition of tuberculin-induced mitogenesis in cultures of lymphocytes from tuberculous donors. Int Arch Allergy Appl Immunol (1966) 1.64
CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol (1984) 1.61
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol (1993) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol (1984) 1.60
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol (1990) 1.59
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene (2006) 1.58
The effect of hydrocortisone on the incorporation of tritiated thymidine by human blood lymphocytes cultured with phytohaemagglutinin and pokeweed mitogen. Clin Exp Immunol (1973) 1.54
The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. J Immunol (1987) 1.50
Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol (1998) 1.43
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res (1991) 1.41
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol (1988) 1.40
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Failure of hydrocortisone to inhibit blastogenesis by pokeweed mitogen in human leucocyte cultures. Clin Exp Immunol (1972) 1.34
Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene (1997) 1.34
Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ (1997) 1.32
Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol (1985) 1.32
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol (1991) 1.31
Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol (1984) 1.30
Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res (1986) 1.29
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer (1995) 1.29
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res (1993) 1.26
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet (1994) 1.25
Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol (1986) 1.24
Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med (1971) 1.21
Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril (1986) 1.19
CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol (1987) 1.19
Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol (2001) 1.19
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res (1999) 1.18
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol (1988) 1.16
The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol (1994) 1.16
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 1.16
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol (1993) 1.16
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J (2000) 1.15
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res (1991) 1.15
Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol (1990) 1.14
CA 125 in ovarian cancer: advances and controversy. Clin Chem (1998) 1.14
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst (1992) 1.13
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J (2000) 1.13
Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer (1983) 1.12
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem (1992) 1.12
Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res (1992) 1.11
Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci (1976) 1.11
The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res (1999) 1.11
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene (2011) 1.11
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res (1999) 1.11
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res (1999) 1.10
Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet (1982) 1.10
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol (1996) 1.08
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol (1992) 1.08
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res (1999) 1.08
Heterogeneity of the cellular immune response. I. Kinetics of lymphocyte stimulation during sensitization and recovery from tolerance. J Exp Med (1971) 1.08
Comparison of lymphocyte transformation and intradermal reactions to tuberculins. Am Rev Respir Dis (1966) 1.08
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer (1994) 1.08
Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol (1986) 1.07
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol (1991) 1.07
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol (1999) 1.06
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol (1986) 1.06
Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Cancer Res (1976) 1.05
Somatic activation of rasK gene in a human ovarian carcinoma. Science (1984) 1.05
An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol (1988) 1.04
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer (1993) 1.04
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer (2001) 1.02
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res (1989) 1.02
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer (1994) 1.02
Mitogenic activity of bacterial fractions in lymphocyte cultures. I. Purified protein derivative and polysaccharides of tuberculin. J Immunol (1966) 1.01
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol (1985) 1.01
Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res (1997) 1.00
Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. J Natl Cancer Inst (1975) 0.99
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res (2000) 0.99
Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. J Natl Cancer Inst (1975) 0.99
Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet (1984) 0.98
Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res (1998) 0.98
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol (1994) 0.98
Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer (2003) 0.98